Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer.

Szczegóły
Abstrakt

Tytuł:: Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer.
Autorzy:: Cox G; Department of Medical Oncology, Leicester Royal Infirmary, Welford Road, Leicester LE1 5WW, UK
Louise Jones J
Andi A
Abrams KR
O'Byrne KJ
Źródło:: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2001 Dec; Vol. 34 (3), pp. 417-26.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: Limerick : Elsevier Scientific Publishers
Original Publication: Amsterdam, The Netherlands : Elsevier, c1985-
MeSH Terms:: Biomarkers, Tumor/*metabolism
Carcinoma, Non-Small-Cell Lung/*pathology
Lung Neoplasms/*pathology
Proto-Oncogene Proteins c-bcl-2/*metabolism
Adult ; Aged ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/surgery ; Chi-Square Distribution ; ErbB Receptors/metabolism ; Female ; Humans ; Immunohistochemistry ; Lung Neoplasms/metabolism ; Lung Neoplasms/surgery ; Male ; Matrix Metalloproteinases/metabolism ; Middle Aged ; Neoplasm Staging/methods ; Neovascularization, Pathologic ; Predictive Value of Tests ; Prognosis ; Proportional Hazards Models ; Retrospective Studies
Substance Nomenclature:: 0 (Biomarkers, Tumor)
0 (Proto-Oncogene Proteins c-bcl-2)
EC 2.7.10.1 (ErbB Receptors)
EC 3.4.24.- (Matrix Metalloproteinases)
Entry Date(s):: Date Created: 20011121 Date Completed: 20030610 Latest Revision: 20190921
Update Code:: 20240104
DOI:: 10.1016/s0169-5002(01)00290-2
PMID:: 11714539
: Czasopismo naukowe

Full Text Finder

Introduction: The underlying biology of a tumour may hold the key to predicting the outcome for an individual patient as well as identifying potential therapeutic targets. Using epidermal growth factor receptor (EGFR) and matrix metalloproteinase (MMP)-9 immunoexpression combined with microvessel counts we have developed a prognostic model for operable non-small cell lung cancer (NSCLC) which predicts outcome independent of stage (Thorax, 56 (2001) 561-566). The aim of this study was to evaluate the impact of bcl-2 expression upon survival in this model.
Methods: This was a retrospective analysis of 167 patients with resected stage I-IIIa NSCLC and >60 days post-operative survival. Minimum follow-up was 2 years. Immunohistochemistry was performed on paraffin-embedded tissue sections for bcl-2, EGFR, MMP-9 and the microvessel marker CD34 to evaluate the relationships between, and impact on survival of these biological markers.
Results: Tumour cell MMP-9 (P=0.002), microvessel count > median (P=0.01), bcl-2 (P=0.02) and stage (P=0.02) were independent prognostic factors. Bcl-2 expression was associated with an improved survival in all sub-groups of our prognostic model.
Conclusion: bcl-2, EGFR and MMP-9 expression and angiogenesis provide prognostic information independent of TNM stage. Prognostic models offer the potential of tailoring the therapeutic management for an individual patient.

Informacja